BioPharma Dive  |  April 21, 2023

Patents as broad as Amgen seeks are “going to mean less treatment options for patients, and at the end of the day, that’s probably not a good thing,” said Sean Tu, a law professor at West Virginia University in Morgantown who co-authored a brief in support of Sanofi, in an interview.

Read more here.